Caribou Biosciences, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Caribou Biosciences, Inc. (CRBU) had Lessee, Operating Lease, Liability, to be Paid, Year One of $4.84 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-03-05
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $4.84M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $4.31M.
- 2024-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $4.41M.
- 2024-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $4.47M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $4.84M 10-K · filed 2026-03-05 |
| 2024-12-31 | $4.31M 10-K · filed 2025-03-10 |
| 2024-09-30 | $4.41M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $4.47M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $4.47M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $3.48M 10-K · filed 2024-03-11 |
| 2023-09-30 | $3.88M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $3.79M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $3.88M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $3.33M 10-K · filed 2023-03-09 |
| 2022-09-30 | $3.20M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $2.94M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $4.21M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $38.30M 10-K · filed 2022-03-21 |
| 2021-09-30 | $3.48M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $3.48M 10-Q · filed 2021-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |